P1-124: Malignant mesothelioma: prognosis not as bad as generally believed
0
Citation
0
Reference
10
Related Paper
Keywords:
Pemetrexed
Carboplatin
Carboplatin
Cite
Citations (69)
Objective To observe the effect and clinical toxicity of pemetrexed combined with carboplatin versus paclitaxel combined with carboplatin with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC).Methods Total of 60 patients stage Ⅲ NSCLC (ⅢA 39 patients,ⅢB 21 patients) were randomly assigned into two groups.Pemetrexed combined with carboplatin group:accepted pemetrexed 500 mg/m2,d1,carboplatin AUC 5,d1,once every 21 days.Paclitaxel combined with carboplatin group:paclitaxel 150 mg/m2,d1,carboplatin AUC 5,d1,once every 21 days.Two groups both accepted 3-D conformal radiation therapy (3D-CRT) during chemotherapy.The total dose was 60 ～ 70 Gy.After radiation therapy,the patients were accepted 2 ～ 3 cycles of chemotherapy.Results The efficacy of pemetrexed combined with carboplatin and paclitaxel combined with carboplatin were 44.83％ and 29.03％ respectively.The disease control rates of two groups were 79.31％ and 67.74％ respectively.The differences were statistically significant (P＜0.05).The adverse reactions of pemetrexed group were rare.Two groups of median progression-free survival were 12.5 and 9.9 months respectively.1 year overall survival was 58.62％ and 48.39％ respectively.The differences were also significant (P＜0.05).Conclusion Pemetrexed combined with carboplatin can be used as stage Ⅲ NSCLC patients treated with concurrent chemoradiation regimens during optimization.Toxicity was tolerable.Pemetrexed group was better than paclitaxel group in disease control rates and survival.
Key words:
Pemetrexed; Paclitaxel; Concurrent chemoradiotherapy; Non-small cell lung cancer
Carboplatin
Pemetrexed
Chemoradiotherapy
Cite
Citations (0)
OBJECTIVE: To explore the clinical effect of gemcitabine compared with carboplatin treatment in advanced non-small cell lung cancer.METHODS: Totally 98 cases with advanced non-small cell lung cancer were randomly divided into group A(gemcitabine compared with carboplatin) and group B(gemcitabine compared with cisplatin).Group A received gemcitabine of 1 000 mg/m2 on day 1 and 8,and carboplatin of AUC 5 on day 1.Group B were given cisplatin 80 mg/m2 on d1 and 2 based on gemcitabine treatment.Twenty-one days were for a cycle and all the patients received 2 cycles of treatments.Effective rate of treatment,1 year survival rate,adverse reaction rate and life quantity were compared between two groups.RESULTS: Effective rates of treatment were 39.7% and 40.0% in group A and group B respectively(P0.05);There were no significant difference of 1 year survival rate between two groups(52.1% vs 45.0%,P0.05);Grade Ⅲ~Ⅳgastrointestinal effect in group A were much less than that in group B(0 vs 12.5%,P0.05);LCSS scores after treatment in group A were superior to group B(P0.05).CONCLUSIONS: Gemcitabine compared with carboplatin or cisplatin treatment in advanced non-small cell lung cancer achieve the same effectiveness.Gemcitabine compared with carboplatin have less adverse reaction rate,and it is well-tolerated for patients.
Carboplatin
Group B
Group A
Cite
Citations (0)
Pemetrexed
Carboplatin
Neoadjuvant Therapy
Clinical endpoint
Cite
Citations (10)
Carboplatin
Cite
Citations (1)
Carboplatin
Regimen
Cite
Citations (15)
Carboplatin
Cite
Citations (4)
Carboplatin
Peritoneal cavity
Cite
Citations (198)
Objective To evaluate the curative effect and toxicity of pemetrexed combined with carboplatin as the first-line treatment of senile patient with advanced non-squamous non-small cell lung cancer.Methods 92 patients with advanced non-squamous non-small cell lung cancer were divided into two groups.The PC group(42 cases) were treated with pemetrexed combined with carboplatin,and the GC group(50 cases) were treated with gemcitabine combined with carboplatin.Results The disease control rate was 73.8% in the PC group and 70.2% in the GC group(P0.05),but the incidence of side effects was significantly lower in the PC group than in the GC group.Conclusion Pemetrexed combined with carboplatin has the similar curative effect with gemcitabine combined with carboplatin in treatment of senile patient with advanced non-squamous non-small cell lung cancer,but it has less side effects and better tolerance than gemcitabine combined with carboplatin.
Carboplatin
Pemetrexed
Cite
Citations (0)
Objective To observe the cytotoxicity of cisplatin combined with carboplatin on osteosarcoma cell line OS-732.Methods Using MTT assay,we obtained the mean IC50 of cisplatin and carboplatin for OS-732 cells.The OS-732 cells were incubated with following drugs for 48 or 72h: IC50 of cisplatin,IC50 of carboplatin,and 1/2 IC50 of cisplatin combined with 1/2 IC50 carboplatin.The cytotoxicity of each group was measured with MTT methods.Results The mean IC50 of cisplatin and carboplatin for osteosarcoma OS-732 cells for 48h was 7.6μg/ml and 199.0μg/ml respectively.The mean cytotoxicity index(CI) of 8.0μg/ml cisplatin, 200.0μg/ml carboplatin and 4.0μg/ml cisplatin+100.0μg/ml carboplatin for 48h were (54.7±5.3)%,(56.9±6.3)% and(57.5±5.7)% respectively(P0.05);and those for 72h were (65.7±4.5)%,(69.4±2.2)% and(68.4±3.6)% respectively,the cytotoxicity index increased significantly in groups containing carboplatin.Conclusion The combination of half dose cisplatin with carboplatin appears to be as active as cisplatin or carboplatin alone in full doses in treatment of osteosarcoma OS-732 cells in vitro.
Carboplatin
MTT assay
IC50
Cite
Citations (0)